Deeper understanding of CLL and the B-cell receptor (BCR) signaling pathway has resulted in the development of new therapeutic approaches that have remarkably improved patient outcomes.6 Among them, new target therapies (ie, kinase and BCL2 inhibitors)6,7 are progressively replacing chemoimmunotherapy. This evidence concerns the gene BCR and B-cell chronic lymphocytic leukemia.